Seres Therapeutics Inc MCRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC)
Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
Seres Shares Down After Co Pauses Drug Development, Lays Off Workers
Trading Information
- Previous Close Price
- $1.41
- Day Range
- $1.33–1.50
- 52-Week Range
- $1.30–29.98
- Bid/Ask
- $1.40 / $1.48
- Shares Outstanding
- 10.20M
- Market Cap
- $14.37M
- Volume/Avg
- 55,575 / 75,410
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 17.71
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 66
Valuation
Metric | MCRB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.68 |
Price/Sales | 17.71 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MCRB |
|---|---|
Quick Ratio | 1.45 |
Current Ratio | 1.65 |
Interest Coverage | — |
Quick Ratio
MCRB
Profitability
Metric | MCRB |
|---|---|
Return on Assets (Normalized) | −46.59% |
Return on Equity (Normalized) | −155.05% |
Return on Invested Capital (Normalized) | −52.70% |
Return on Assets
MCRB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|f&QXwv | LOCK|Cn>#N | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|VFn@Ch | LOCK|bq<kz | $99B | |||
| Moderna Inc MRNA | LOCK|#RwWs< | LOCK|G!< | $84B | |||
| argenx SE ADR ARGX | LOCK|ZBNTX@ | LOCK|$L | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|b!%mTZB | LOCK|@Px | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|^@N$<#?? | LOCK|^Vfy | $31B | |||
| Incyte Corp INCY | LOCK|&KzP^gQ | LOCK|P!M | $24B | |||
| BioNTech SE ADR BNTX | LOCK|r$!CWB | LOCK|#M | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^^@g$s@ | LOCK|!d&D | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|W@B$JB | LOCK|K% | $15B |